Clinical trial results published by our Clinical Trials Unit show that women treated with 6 months of Herceptin for HER2 positive early breast cancer did as well in terms of their risk of breast cancer returning as those getting the currently conventional 12 months treatment.
HTA's 1000th issue features the results of the ground breaking PARAMEDIC trial. View the journal online
A process evaluation of the WHiTE Two trial comparing THA with and without dual mobility component
Read the full article in Bone and Joint Research
New imaging scans track down persistent cancer cells.
Read the full article in NEJM